BioSpace, a biotechnology company, announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has authorized the use of Nuvaxovid™ as a booster dose in adults aged 18 and older. The announcement from BioSpace mentioned that Nuvaxovid™ is also available as a booster in adults in the following countries: U.S., European Union, Japan, Australia, New Zealand, Switzerland, and Israel.
MHRA has also approved a Pfizer/BioNTech bivalent booster vaccine. This vaccine targets the original strain of SARS-CoV-2 and Omicron BA.4 and BA.5 sub-variants. This is the second bivalent vaccine from Pfizer/BioNTech to receive approval from MHRA. Individuals aged 12 years and above are approved to receive this booster dose.